Oge O, Atsü N, Sahin A, Ozen H
Department of Urology, Hacettepe University School of Medicine, Ankara, Turkey.
Scand J Urol Nephrol. 2000 Dec;34(6):349-51. doi: 10.1080/003655900455404.
This study aimed to compare the BTA (bladder tumour antigen) stat and urinary nuclear matrix protein (NMP22) tests in the detection of bladder cancer.
The office-based qualitative BTA stat and the laboratory-based quantitative NMP22 tests were studied in the same urine samples obtained from 49 patients with a high suspicion of bladder cancer and 20 healthy subjects.
A tumour was identified in 36 patients after the cystoscopy. BTA stat demonstrated a sensitivity of 89%, which was superior to the sensitivity of 66.6% with the NMP22 test in detecting the bladder cancer (p < 0.02). The sensitivities for grade I tumours with BTA stat and NMP22 were 55.5% and 33.3%, respectively. The sensitivity of BTA stat was 100% for tumour categories except for the pTa and grade I tumours. No positive result was observed with both tests among the healthy subjects. The specificities for BTA stat and NMP22 were 78.7% and 69.6%, respectively.
The BTA stat test was significantly more sensitive than the NMP22 test in the detection of bladder cancer. Although the sensitivity of BTA stat was not sufficient to replace cystoscopy, its ease and low cost may play a role in reducing the number of control cystoscopies, especially in patients with low risk of progression.
本研究旨在比较膀胱肿瘤抗原(BTA)快速检测法和尿核基质蛋白(NMP22)检测法在膀胱癌检测中的效果。
对从49例高度怀疑患有膀胱癌的患者及20名健康受试者采集的相同尿液样本进行研究,分别采用门诊定性BTA快速检测法和实验室定量NMP22检测法。
36例患者经膀胱镜检查发现有肿瘤。BTA快速检测法的灵敏度为89%,在检测膀胱癌方面优于NMP22检测法66.6%的灵敏度(p < 0.02)。BTA快速检测法和NMP22检测法对I级肿瘤检测的灵敏度分别为55.5%和33.3%。除pTa和I级肿瘤外,BTA快速检测法对其他肿瘤类别的灵敏度为100%。在健康受试者中,两种检测方法均未出现阳性结果。BTA快速检测法和NMP22检测法的特异性分别为78.7%和69.6%。
在膀胱癌检测中,BTA快速检测法比NMP22检测法明显更敏感。尽管BTA快速检测法的灵敏度不足以替代膀胱镜检查,但其简便性和低成本可能有助于减少膀胱镜复查次数,尤其是对于进展风险较低的患者。